Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, and Tropicamide, the active ingredients in Mydrane, are local anesthetic and mydriatic agents presented as an intracameral solution for intracameral use. It provides intra‑ocular anesthesia and pupil dilation during cataract surgery.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and surgical centres worldwide.

Mydrane is used in ophthalmic procedures that require both anesthesia and pupil dilation.

Cataract surgery: provides rapid pupil dilation and intra‑ocular anesthesia to facilitate lens removal. Intraocular anesthesia during cataract extraction: ensures patient comfort and a motion‑less eye. Other anterior segment surgeries: assists in procedures such as trabeculectomy by maintaining a dilated pupil and providing local analgesia.

Mydrane may cause a range of ocular and systemic reactions.

Common Side Effects: - Transient ocular pain or discomfort. - Redness or conjunctival hyperemia. - Temporary increase in intra‑ocular pressure. - Blurred vision lasting a few hours. - Mild headache. - Nausea or mild systemic dizziness.

Serious or Rare Side Effects: - Allergic reaction including rash, itching, or anaphylaxis. - Sustained mydriasis leading to photophobia. - Corneal edema or endothelial damage. - Retinal toxicity. - Systemic lidocaine toxicity presenting as seizures or cardiac arrhythmia. - Severe hypotension from systemic phenylephrine absorption.

When using Mydrane, consider the following safety measures.

Allergy assessment: verify no hypersensitivity to lidocaine, phenylephrine, or tropicamide. Intra‑ocular pressure monitoring: measure IOP before and after injection. Cardiovascular stability: avoid in patients with uncontrolled hypertension or severe cardiac disease. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Concurrent mydriatics: avoid combining with other strong mydriatic agents. Store at ambient temperature: keep in the original container, protect from light and moisture.

Mydrane can interact with other medications; awareness of the interaction level is essential.

Major Interactions (Avoid): - Systemic phenylephrine or other α1‑agonists: may cause severe hypertension. - Concurrent local anesthetics: risk of additive lidocaine toxicity. - MAO inhibitors combined with phenylephrine: potential hypertensive crisis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the IOP‑lowering effect of phenylephrine. - Cholinergic agents (e.g., pilocarpine): may reduce the mydriatic effect of tropicamide. - Anticholinergic drugs: may enhance tropicamide‑related systemic anticholinergic effects.